Aura Biosciences Inc. Common Stock (AURA)
Stock · NASDAQ · Health Care
$6.11as of 10/16/2026
Price chart
Active signals
AURA Signal Track Record
How signals performed across all stocks →What AURA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -5.2% | 26% | October 2, 2026 |
| Bollinger Band Breakdown | 22 | -3.1% | 32% | September 10, 2026 |
| Bollinger Band Breakout | 20 | -4.9% | 35% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -4.9% | 31% | September 17, 2026 |
| Any 20-session window (baseline) | -2.4% | 42% |
Computed by MarketWall from daily closing prices since August 16, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AURA
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 113
- Website
- aurabiosciences.com/
Fundamentals
- 1-day range
- $6.1$6.35
- Market cap
- $798.53M
- P/E (trailing)
- —
- P/E (forward)
- -3.00
- EPS (trailing)
- $-1.76
- Dividend yield
- —
- Beta
- 0.45
- Avg. volume
- 801.4K
Forecasts
5 analyst ratings
Aura Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AURAAura Biosciences Inc. Common Stock$6.1▼ 3.79%Market cap $798.53MP/E —$4.73$9.54
- DBVTDBV Technologies S.A. American Depositary Shares$9.05▼ 0.66%Market cap $813.58MP/E —$1.57$4.5
- CADLCandel Therapeutics Inc. Common Stock$8.19▼ 8.08%Market cap $775.20MP/E —$4.35$14
- SLDBSolid Biosciences Inc. Common Stock$5.53▼ 3.66%Market cap $857.50MP/E —$3.79$11.45
- ALLOAllogene Therapeutics Inc. Common Stock$1.31▼ 2.24%Market cap $679.95MP/E —$1.04$4.46
- ATTOAttovia Therapeutics Inc. Common Stock$13.73▼ 7.10%Market cap $928.90MP/E 0.00$14.23$28
- AGMBAgomAb Therapeutics NV American Depositary Shares$8.28▼ 0.60%Market cap $664.85MP/E —$7.97$17.82
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AURA Aura Biosciences Inc. Common Stock | $798.53M | — | $6.1 | ▼ 3.79% | $4.73$9.54 |
| DBVT DBV Technologies S.A. American Depositary Shares | $813.58M | — | $9.05 | ▼ 0.66% | $1.57$4.5 |
| CADL Candel Therapeutics Inc. Common Stock | $775.20M | — | $8.19 | ▼ 8.08% | $4.35$14 |
| SLDB Solid Biosciences Inc. Common Stock | $857.50M | — | $5.53 | ▼ 3.66% | $3.79$11.45 |
| ALLO Allogene Therapeutics Inc. Common Stock | $679.95M | — | $1.31 | ▼ 2.24% | $1.04$4.46 |
| ATTO Attovia Therapeutics Inc. Common Stock | $928.90M | 0.00 | $13.73 | ▼ 7.10% | $14.23$28 |
| AGMB AgomAb Therapeutics NV American Depositary Shares | $664.85M | — | $8.28 | ▼ 0.60% | $7.97$17.82 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Kratz Erica · September 1, 2026 · Grant199.1K
- Kratz Erica · September 1, 2026 · Grant100.9K
- Abu-Absi Susan · September 1, 2026 · Grant265.5K
- Abu-Absi Susan · September 1, 2026 · Grant134.5K
- Amy Elazzouzi · September 1, 2026 · Grant46.5K
- Amy Elazzouzi · September 1, 2026 · Grant23.5K
- Janet Jill Hopkins · September 1, 2026 · Grant116.2K
- Janet Jill Hopkins · September 1, 2026 · Grant58.9K
- Person Julie · September 1, 2026 · Grant212.4K
- Person Julie · September 1, 2026 · Grant107.6K
- Jeremy Bender · July 7, 2026 · Grant60.0K
- Jeremy Bender · July 7, 2026 · Grant30.0K
- Conor Kilroy · July 1, 2026 · Grant14.9K
- Anthony S. Gibney · June 16, 2026 · Sale12.8K @ $6.42
- Sapna Srivastava · June 11, 2026 · Grant30.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 50.35M
- Total value held
- $334.03M
- Institutional holders
- 121
- Unknown6.92M
- Unknown5.10M
- Unknown4.88M
- Unknown4.62M
- Unknown4.37M
- Unknown3.59M
- Unknown3.04M
- Unknown2.24M
- Unknown2.12M
- Unknown2.07M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Aura Biosciences Announces Conference Participation and Inducement Grants
Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.
Aura Biosciences Announces Conference Participation and Inducement Grants. Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.